Sun, 02/27/2022 | News

AusVaxSafety actively monitoring Novavax COVID-19 vaccine safety

With the Nuvaxovid (Novavax) COVID-19 vaccine now available at GP clinics, pharmacies and vaccination hubs across Australia, AusVaxSafety has started active surveillance of the safety and adverse event profile of the vaccine.

AusVaxSafety sends out a short online survey via SMS or email to individuals who receive their Novavax COVID-19 vaccine at a participating AusVaxSafety site, allowing participants to report any adverse events they may have experienced at different time points after their vaccination. 

De-identified data from completed surveys are analysed and monitored by epidemiologists and vaccine experts to ensure that the vaccine is performing as safely and effectively as it is expected to.

The addition of the Novavax COVID-19 vaccine to the AusVaxSafety program builds on the ongoing surveillance of the Comirnaty (Pfizer), Spikevax (Moderna) and Vaxzevria (AstraZeneca) COVID-19 vaccines, ensuring the safety of all COVID-19 vaccines being used in Australia is monitored.

Since February 2021, more than 2.5 million Australians have participated in the AusVaxSafety COVID-19 vaccine surveillance program, by completing more than 6 million safety surveys, making this the largest scale active vaccine safety surveillance ever conducted in Australia.

Novavax COVID-19 vaccine safety data will be available on the AusVaxSafety website shortly and once published, the data will be updated weekly.

Access COVID-19 vaccine safety data here
 

Photo by Piero Nigro on Unsplash